Compare EUDA & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | NNVC |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | Singapore | United States |
| Employees | 117 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 21.2M |
| IPO Year | N/A | 2008 |
| Metric | EUDA | NNVC |
|---|---|---|
| Price | $14.10 | $1.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $55.00 | N/A |
| AVG Volume (30 Days) | ★ 325.3K | 292.6K |
| Earning Date | 12-19-2023 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $134.73 | N/A |
| Revenue Next Year | $195.03 | N/A |
| P/E Ratio | $123.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.85 |
| 52 Week High | $25.70 | $2.23 |
| Indicator | EUDA | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 62.67 | 64.06 |
| Support Level | $1.87 | $1.35 |
| Resistance Level | $15.36 | $1.53 |
| Average True Range (ATR) | 4.44 | 0.12 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 42.03 | 67.32 |
EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.